Abstract
The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cellfree DNA has been tested for quantity, fragmentation pattern and tumor-specific sequences in patients with various malignancies. The introduction of improved detection methods showed that all these alterations are regularly detectable in many cancer patients and the investigation of cell-free DNA may provide useful diagnostic and prognostic information. Herein, we review the recent findings on cell-free DNA alterations in patients with prostate cancer and discuss its diagnostic and prognostic potential.
Keywords: Prostate cancer, DNA fragmentation, cell-free DNA, DNA methylation, allelic imbalance.
Current Cancer Therapy Reviews
Title:Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer
Volume: 9 Issue: 4
Author(s): Stefan Latz, Stefan C. Muller and Jorg Ellinger
Affiliation:
Keywords: Prostate cancer, DNA fragmentation, cell-free DNA, DNA methylation, allelic imbalance.
Abstract: The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cellfree DNA has been tested for quantity, fragmentation pattern and tumor-specific sequences in patients with various malignancies. The introduction of improved detection methods showed that all these alterations are regularly detectable in many cancer patients and the investigation of cell-free DNA may provide useful diagnostic and prognostic information. Herein, we review the recent findings on cell-free DNA alterations in patients with prostate cancer and discuss its diagnostic and prognostic potential.
Export Options
About this article
Cite this article as:
Latz Stefan, Muller Stefan C. and Ellinger Jorg, Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418094329
DOI https://dx.doi.org/10.2174/157339470904140418094329 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Polysaccharide-Protein Nanoassemblies: Novel Soft Materials for Biomedical and Biotechnological Applications
Current Protein & Peptide Science Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Current Cancer Drug Targets Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Human Complex Trait Genetics: Lifting the Lid of the Genomics Toolbox - from Pathways to Prediction
Current Genomics In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Current Pharmaceutical Biotechnology Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy New Approaches to Target the Androgen Receptor and STAT3 for Prostate Cancer Treatments
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Apoptosis in Carcinogenesis and Cancer Therapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Cancer Drug Targets “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters MicroRNA and Exosome in Retinal-related Diseases: Their Roles in the Pathogenesis and Diagnosis
Combinatorial Chemistry & High Throughput Screening High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Towards Environmental Construct Validity in Animal Models of CNS Disorders: Optimizing Translation of Preclinical Studies
CNS & Neurological Disorders - Drug Targets Role of Stem Cells in Normal Liver and Cancer
Anti-Cancer Agents in Medicinal Chemistry Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews